搜索到 1000 条关于 백링크 작업 vsa822.top 텔레그램 자동 홍보 무료 마케팅 프로그램 블로그 자동 포스팅 프로그램 sA 的文章
-
-
2013.12.25 盘点2013年改变世界的5大重磅新药
2013年岁末已至,回首这一年,一批"重磅炸弹"级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top...积极的数据。制药巨头正准备将晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2:糖尿病治疗的新突破强生和Evotec公司
-
2012.09.19 第一届分析大会
论坛8-2:原子光谱论坛820:原子吸收光谱及其分析应用论坛821:仪器,原子化器与双光束系统论坛822:等离子光谱仪(电感耦合
-
-
2016.08.09 七夕节:话一话古代十大奇葩避孕方式
CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入
-
2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)
时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd会议简介
According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
5 Reasons To Attend - Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
- Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
- The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
- Showcasing unique case studies from leading Asian and international biosimilar companies
- Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success
Industry Gurus / Speakers Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals Past Attendees Include Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)Registration FEES per delegate Early Bird Rate
Register & Pay before 11 March 2011Special Rate
Register & Pay before 15 April 2011Normal Rate
Register & Pay after 15 April 2011Group Rate
Group of 3 or more? US$ / CNYUS$ / CNYUS$ / CNYUS$ / CNY4 day package
(Conf + Pre & Post Workshops)2,495 /
16,6002,695 /
17,9502,895 /
19,5002,175 /
14,6503.5 day package (Conf + Workshop C & A or B ) 2,295 /
15,5002,495 /
16,6002,695 /
17,9502,025 /
13,5003 day package (Conf + Workshop A & B or C) 1,995 /
13,5002,195 /
14,6002,395 /
15,9501,795 /
12,0002.5 day package (Conf + Workshop A or B) 1,795 /
12,0001,995 /
13,5002,195 /
14,6001,695 /
10,9502 day package
(Conf only)1,495 /
9,9501,695 /
11,3001,895 /
12,6001,495 /
9,950PAYMENT TERMS
Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.Payments by Singapore Dollars (S$)
Payments by RMB (CNY)- Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
- Payment by telegraphic transfer in S$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 147-059513-001 (SGD)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232 - Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
- Payment by telegraphic transfer in CNY must be made to:
A/C Name:
A/C No.: 720-031103-001
Beneficiary Bank:
Bank Address: No. 1000 Lujiazui Rind Road,
Pudong, Shanghai 200120, P.R. China
Bank Swift Code: HSBCCNSH
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.联系方式电话:+65 650 82401
-
2023.11.15 Nature 子刊!国内团队新型递送策略实现时空控制,抑制肿瘤转移
)GzmB 介导的 CDH5(购自义翘神州,货号:50192-M08H)裂解的蛋白印迹结果。箭头指示 CDH5 裂解的片段,丝氨酸蛋白酶抑制剂 SA3N 的存在
-
-
2023.11.01 CAR-T 的「阿喀琉斯之踵」和 CAR-DNT 的中国雄心
] Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf'
-
-
2021.08.04 慢性中性粒细胞白血病
,Harris NL,Jaffe ES,Pileri SA,Stein H,Thiele J(Eds):WHO Classification
-
-
2020.10.09 如何避免 BD 药物治疗不良反应?试试这个方案!
SA, Kim MK. Effect of Low Frequency Repetitive Transcranial Magnetic Stimulation
-
-
2020.05.29 2020 年华大基因肿瘤医学成果展示:3 款最新肿瘤检测技术,助力癌症防控
]LanmanRB, Mortimer SA, ZillOA, et al. Analytical and clinical validation of a digital